Is SRNE or ZVSA more profitable?

Sorrento Therapeutics' return on equity of 0.00% beat ZyVersa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sorrento Therapeutics N/A N/A N/A ZyVersa Therapeutics N/A -109.54% -43.95%

Is SRNE or ASLN more profitable?

Sorrento Therapeutics' return on equity of 0.00% beat ASLAN Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Sorrento Therapeutics N/A N/A N/A ASLAN Pharmaceuticals N/A -8,454.87% -121.60%

Do analysts recommend PRFX or SRNE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sorrento Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is PRFX or SRNE more profitable?

Company Net Margins Return on Equity Return on Assets PainReform N/A N/A N/A Sorrento Therapeutics N/A N/A N/A

Does the media refer more to SRNE or EVFM?

In the previous week, Sorrento Therapeutics and Sorrento Therapeutics both had 1 articles in the media. Evofem Biosciences' average media sentiment score of 0.84 beat Sorrento Therapeutics' score of 0.75 indicating that Evofem Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sorrento Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evofem Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate SRNE or ONCO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sorrento Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Onconetix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Sorrento Therapeutics (SRNE) Competitors

$0.0006 0.00 (0.00%)

As of 07/2/2026 03:30 PM Eastern

Compare

SRNE vs. ZVSA, ASLN, PRFX, EVFM, and ONCO

Should you buy Sorrento Therapeutics stock or one of its competitors? MarketBeat compares Sorrento Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sorrento Therapeutics include ZyVersa Therapeutics (ZVSA), ASLAN Pharmaceuticals (ASLN), PainReform (PRFX), Evofem Biosciences (EVFM), and Onconetix (ONCO). These companies are all part of the "pharmaceutical products" industry.

How does Sorrento Therapeutics compare to ZyVersa Therapeutics?

Sorrento Therapeutics (NASDAQ:SRNE) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Sorrento Therapeutics has a beta of 0.1, meaning that its stock price is 90% less volatile than the broader market. Comparatively, ZyVersa Therapeutics has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market.

0.0% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are held by institutional investors. 2.6% of Sorrento Therapeutics shares are held by company insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Sorrento Therapeutics' return on equity of 0.00% beat ZyVersa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sorrento Therapeutics	N/A	N/A	N/A
ZyVersa Therapeutics	N/A	-109.54%	-43.95%

In the previous week, Sorrento Therapeutics had 1 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 1 mentions for Sorrento Therapeutics and 0 mentions for ZyVersa Therapeutics. Sorrento Therapeutics' average media sentiment score of 0.75 beat ZyVersa Therapeutics' score of 0.00 indicating that Sorrento Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Sorrento Therapeutics	Positive
ZyVersa Therapeutics	Neutral

ZyVersa Therapeutics has lower revenue, but higher earnings than Sorrento Therapeutics. ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sorrento Therapeutics	$60.32M	0.01	-$572.84M	-$0.43	N/A
ZyVersa Therapeutics	N/A	N/A	-$9.41M	-$0.83	N/A

Summary

Sorrento Therapeutics beats ZyVersa Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Sorrento Therapeutics compare to ASLAN Pharmaceuticals?

Sorrento Therapeutics (NASDAQ:SRNE) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

0.0% of Sorrento Therapeutics shares are owned by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. 2.6% of Sorrento Therapeutics shares are owned by insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Sorrento Therapeutics has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

ASLAN Pharmaceuticals has lower revenue, but higher earnings than Sorrento Therapeutics. ASLAN Pharmaceuticals is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sorrento Therapeutics	$60.32M	0.01	-$572.84M	-$0.43	N/A
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A

Sorrento Therapeutics' return on equity of 0.00% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sorrento Therapeutics	N/A	N/A	N/A
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%

In the previous week, Sorrento Therapeutics had 1 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 1 mentions for Sorrento Therapeutics and 0 mentions for ASLAN Pharmaceuticals. Sorrento Therapeutics' average media sentiment score of 0.75 beat ASLAN Pharmaceuticals' score of 0.00 indicating that Sorrento Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Sorrento Therapeutics	Positive
ASLAN Pharmaceuticals	Neutral

Summary

Sorrento Therapeutics beats ASLAN Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Sorrento Therapeutics compare to PainReform?

PainReform (NASDAQ:PRFX) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sorrento Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

PainReform has higher earnings, but lower revenue than Sorrento Therapeutics. PainReform is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$20K	59.16	-$5.02M	-$736.66	N/A
Sorrento Therapeutics	$60.32M	0.01	-$572.84M	-$0.43	N/A

PainReform has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market. Comparatively, Sorrento Therapeutics has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market.

In the previous week, Sorrento Therapeutics had 1 more articles in the media than PainReform. MarketBeat recorded 1 mentions for Sorrento Therapeutics and 0 mentions for PainReform. Sorrento Therapeutics' average media sentiment score of 0.75 beat PainReform's score of 0.00 indicating that Sorrento Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
PainReform	Neutral
Sorrento Therapeutics	Positive

Company	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
Sorrento Therapeutics	N/A	N/A	N/A

37.3% of PainReform shares are owned by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are owned by institutional investors. 34.4% of PainReform shares are owned by company insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

PainReform beats Sorrento Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Sorrento Therapeutics compare to Evofem Biosciences?

Sorrento Therapeutics (NASDAQ:SRNE) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

0.0% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are held by institutional investors. 2.6% of Sorrento Therapeutics shares are held by company insiders. Comparatively, 0.0% of Evofem Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Sorrento Therapeutics and Sorrento Therapeutics both had 1 articles in the media. Evofem Biosciences' average media sentiment score of 0.84 beat Sorrento Therapeutics' score of 0.75 indicating that Evofem Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sorrento Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evofem Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sorrento Therapeutics has a beta of 0.1, suggesting that its share price is 90% less volatile than the broader market. Comparatively, Evofem Biosciences has a beta of -1.33, suggesting that its share price is 233% less volatile than the broader market.

Sorrento Therapeutics has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Sorrento Therapeutics' return on equity of 0.00% beat Evofem Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sorrento Therapeutics	N/A	N/A	N/A
Evofem Biosciences	-46.42%	-91.97%	-61.93%

Evofem Biosciences has lower revenue, but higher earnings than Sorrento Therapeutics. Evofem Biosciences is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sorrento Therapeutics	$60.32M	0.01	-$572.84M	-$0.43	N/A
Evofem Biosciences	$11.39M	0.09	$52.98M	-$0.07	N/A

Summary

Sorrento Therapeutics beats Evofem Biosciences on 7 of the 12 factors compared between the two stocks.

How does Sorrento Therapeutics compare to Onconetix?

Sorrento Therapeutics (NASDAQ:SRNE) and Onconetix (NASDAQ:ONCO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

0.0% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 23.9% of Onconetix shares are held by institutional investors. 2.6% of Sorrento Therapeutics shares are held by insiders. Comparatively, 0.3% of Onconetix shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Sorrento Therapeutics had 1 more articles in the media than Onconetix. MarketBeat recorded 1 mentions for Sorrento Therapeutics and 0 mentions for Onconetix. Sorrento Therapeutics' average media sentiment score of 0.75 beat Onconetix's score of 0.00 indicating that Sorrento Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Sorrento Therapeutics	Positive
Onconetix	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sorrento Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Sorrento Therapeutics has a net margin of 0.00% compared to Onconetix's net margin of -1,316.28%. Sorrento Therapeutics' return on equity of 0.00% beat Onconetix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sorrento Therapeutics	N/A	N/A	N/A
Onconetix	-1,316.28%	-101.08%	-47.34%

Sorrento Therapeutics has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market. Comparatively, Onconetix has a beta of 2.69, meaning that its share price is 169% more volatile than the broader market.

Onconetix has lower revenue, but higher earnings than Sorrento Therapeutics. Sorrento Therapeutics is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sorrento Therapeutics	$60.32M	0.01	-$572.84M	-$0.43	N/A
Onconetix	$735.20K	1.48	-$14.03M	$11.40	0.08

Summary

Sorrento Therapeutics and Onconetix tied by winning 7 of the 14 factors compared between the two stocks.

Get Sorrento Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SRNE vs. The Competition

Export

Metric	Sorrento Therapeutics	Biological Products Industry	Medical Sector	NASDAQ Exchange
Market Cap	$331K	$353.15M	$7.16B	$12.48B
Dividend Yield	N/A	N/A	2.66%	6.52%
P/E Ratio	0.00	N/A	28.02	24.70
Price / Sales	0.01	228.84	540.37	99.49
Price / Cash	N/A	22.44	49.26	57.09
Price / Book	N/A	4.86	10.96	6.46
Net Income	-$572.84M	-$141.03M	$3.57B	$337.01M
7 Day Performance	N/A	2.78%	2.12%	1.69%
1 Month Performance	N/A	7.12%	5.25%	3.81%
1 Year Performance	N/A	77.98%	33.29%	23.90%

Sorrento Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SRNE Sorrento Therapeutics	N/A	$0.00 flat	N/A	-53.8%	$331K	$60.32M	N/A	800
ZVSA ZyVersa Therapeutics	N/A	$0.16 -0.1%	N/A	-78.8%	$1.27M	N/A	N/A	2	Gap Up
ASLN ASLAN Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$1.23M	$12M	N/A	30
PRFX PainReform	0.6855 of 5 stars	$1.38 -2.1%	N/A	-81.0%	$1.22M	$20K	N/A	4
EVFM Evofem Biosciences	N/A	$0.01 -3.6%	N/A	-20.0%	$1.10M	$11.39M	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SRNE) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sorrento Therapeutics (SRNE) Competitors

SRNE vs. ZVSA, ASLN, PRFX, EVFM, and ONCO

How does Sorrento Therapeutics compare to ZyVersa Therapeutics?

Summary

How does Sorrento Therapeutics compare to ASLAN Pharmaceuticals?

Summary

How does Sorrento Therapeutics compare to PainReform?

Summary

How does Sorrento Therapeutics compare to Evofem Biosciences?

Summary

How does Sorrento Therapeutics compare to Onconetix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRNE vs. The Competition

Sorrento Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sorrento Therapeutics (SRNE) Competitors

SRNE vs. ZVSA, ASLN, PRFX, EVFM, and ONCO

How does Sorrento Therapeutics compare to ZyVersa Therapeutics?

Which has more volatility & risk, SRNE or ZVSA?

Do institutionals & insiders believe in SRNE or ZVSA?

Is SRNE or ZVSA more profitable?

Does the media refer more to SRNE or ZVSA?

Which has preferable earnings and valuation, SRNE or ZVSA?

Summary

How does Sorrento Therapeutics compare to ASLAN Pharmaceuticals?

Do insiders and institutionals hold more shares of SRNE or ASLN?

Which has more risk & volatility, SRNE or ASLN?

Which has better valuation and earnings, SRNE or ASLN?

Is SRNE or ASLN more profitable?

Does the media favor SRNE or ASLN?

Summary

How does Sorrento Therapeutics compare to PainReform?

Do analysts recommend PRFX or SRNE?

Which has stronger valuation and earnings, PRFX or SRNE?

Which has more volatility & risk, PRFX or SRNE?

Does the media refer more to PRFX or SRNE?

Is PRFX or SRNE more profitable?

Do insiders and institutionals have more ownership in PRFX or SRNE?

Summary

How does Sorrento Therapeutics compare to Evofem Biosciences?

Do institutionals and insiders believe in SRNE or EVFM?

Does the media refer more to SRNE or EVFM?

Which has more risk and volatility, SRNE or EVFM?

Is SRNE or EVFM more profitable?

Which has higher valuation & earnings, SRNE or EVFM?

Summary

How does Sorrento Therapeutics compare to Onconetix?

Do insiders & institutionals hold more shares of SRNE or ONCO?

Does the media prefer SRNE or ONCO?

Do analysts rate SRNE or ONCO?

Is SRNE or ONCO more profitable?

Which has more volatility & risk, SRNE or ONCO?

Which has preferable valuation & earnings, SRNE or ONCO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRNE vs. The Competition

Sorrento Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools